Specify a stock or a cryptocurrency in the search bar to get a summary
Sanbio Company Limited
4592SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan. Address: St. Luke Tower, Tokyo, Japan, 104-0044
Analytics
WallStreet Target Price
175 580.67 JPYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4592
Dividend Analytics 4592
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4592
Stock Valuation 4592
Financials 4592
Results | 2019 | Dynamics |